Hantavirus Outbreak Sparks Volatility in Biotech Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy INO?
Source: Fool
- Market Reaction: The hantavirus outbreak has triggered investor interest, leading biotech stocks like Moderna, Novavax, and Inovio to rise significantly over the past week, reflecting market sensitivity to vaccine development and speculative sentiment.
- CDC Risk Assessment: The Centers for Disease Control and Prevention (CDC) has stated that the risk of hantavirus transmission is extremely low, emphasizing that infection requires close contact with an infected person, which alleviates some market fears and reduces panic.
- Moderna's Development Update: Moderna announced it is working on a hantavirus treatment, currently in early stages, but its stock surged due to market confidence in its mRNA platform, demonstrating ongoing investor interest in vaccine development.
- Cautious Investor Sentiment: Despite the short-term rise in biotech stocks driven by the outbreak, analysts note that these market fluctuations are sentiment-driven and do not reflect fundamentals, urging investors to be cautious and avoid following the hype blindly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.410
Low
3.00
Averages
7.33
High
13.00
Current: 1.410
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovalis Real Estate Investment Trust Q1 Financial Results
- Decline in Rental Revenue: Inovalis Real Estate Investment Trust reported Q1 2026 rental revenue of $5.42 million, a 16.6% year-over-year decline, indicating weakened market demand and reduced leasing activity, which could negatively impact future cash flows.
- FFO Calculation Adjustment: Management excluded $17,020 of non-recurring finance income related to the Trio disposition from the Q1 2026 FFO calculation, reflecting a more conservative approach in financial reporting to ensure accurate investor understanding of financial health.
- Zero FFO and AFFO per Unit: The FFO and AFFO per unit for Q1 2026 were both nil, consistent with current occupancy levels and borrowing costs, highlighting challenges in operational efficiency and profitability that may affect investor confidence.
- Market Environment Impact: Given the significant declines in rental revenue and FFO, Inovalis may need to reassess its investment strategy and asset management to adapt to the changing market environment and maintain competitiveness.
See More
Inovio Pharmaceuticals Set to Announce Q1 Earnings on May 13
- Earnings Announcement: Inovio Pharmaceuticals is set to release its Q1 2023 earnings report on May 13 after market close, with consensus EPS estimate at -$0.33 and revenue estimate at $0.25 million, reflecting the company's commitment to financial transparency.
- Historical Performance Review: Over the past year, Inovio has exceeded EPS estimates 50% of the time and revenue estimates 25% of the time, indicating a mixed ability to meet market expectations while facing ongoing challenges.
- Estimate Changes: In the last three months, EPS estimates have seen two upward revisions and one downward revision, highlighting analysts' differing views on the company's future performance, which may impact investor confidence and stock price volatility.
- Financing Activity: Inovio recently priced a public offering of shares and warrants at $17.5 million to enhance liquidity and support its R&D projects, indicating a proactive strategy in capital raising efforts.
See More
Hantavirus Outbreak Sparks Volatility in Biotech Stocks
- Market Reaction: The hantavirus outbreak has triggered investor interest, leading biotech stocks like Moderna, Novavax, and Inovio to rise significantly over the past week, reflecting market sensitivity to vaccine development and speculative sentiment.
- CDC Risk Assessment: The Centers for Disease Control and Prevention (CDC) has stated that the risk of hantavirus transmission is extremely low, emphasizing that infection requires close contact with an infected person, which alleviates some market fears and reduces panic.
- Moderna's Development Update: Moderna announced it is working on a hantavirus treatment, currently in early stages, but its stock surged due to market confidence in its mRNA platform, demonstrating ongoing investor interest in vaccine development.
- Cautious Investor Sentiment: Despite the short-term rise in biotech stocks driven by the outbreak, analysts note that these market fluctuations are sentiment-driven and do not reflect fundamentals, urging investors to be cautious and avoid following the hype blindly.
See More
Hantavirus Outbreak Triggers Surge in Pharma Stocks
- Pharma Stock Surge: Following the WHO's May 2 warning about the hantavirus outbreak, Moderna's stock rose 7% in premarket trading, indicating market confidence in its ability to address emerging infectious diseases.
- Research Collaboration: Moderna is conducting preclinical research on hantaviruses in collaboration with the US Army Medical Research Institute, although Evercore ISI believes this will not lead to significant revenue opportunities, it highlights the agility of its mRNA platform.
- Other Companies' Performance: Inovio Pharmaceuticals jumped 11% in early trading, while Novavax rose 5%, reflecting positive market sentiment towards vaccine development firms, despite limited overall market opportunities.
- Epidemic Control Status: President Trump stated that the outbreak on the cruise ship is under control, with the WHO reporting 8 confirmed cases and 3 deaths, assessing the public health risk as low, indicating the situation is manageable.
See More
Hantavirus Outbreak Drives Pharmaceutical Stocks Up
- Pharmaceutical Stocks Surge: Following the hantavirus outbreak, pharmaceutical stocks such as Moderna, Inovio, Novavax, and Emergent Biosolutions saw significant premarket gains, with Moderna rising 7%, Inovio up 13%, and Emergent and Novavax increasing by 4% and 3% respectively, indicating heightened investor interest in outbreak-related companies.
- Market Reaction Analysis: Evercore ISI analysts noted that despite the stock increases, the revenue opportunity from hantavirus is limited, suggesting that the current price fluctuations are primarily sentiment-driven rather than based on fundamental changes, and highlighting that Moderna's mRNA platform agility is already well understood by the market.
- Epidemic Background: The World Health Organization confirmed the hantavirus outbreak on May 2, stating that the virus is transmitted by rodents; although there have been 8 reported cases and 3 deaths, the public health risk is assessed as low, indicating that the severity of the outbreak is limited.
- Government Response Measures: U.S. President Trump stated that the outbreak is under control and promised a report on the virus soon, emphasizing the government's proactive stance in managing the situation, which may further influence market sentiment and investor confidence.
See More
Rare Hantavirus Outbreak Sparks Market Response
- Outbreak Overview: The WHO reports at least six confirmed infections and three deaths linked to the hantavirus outbreak, specifically the Andes strain, which is one of the few variants associated with limited person-to-person transmission, although the public risk remains low.
- Market Response: Following the confirmation of a positive case in an evacuated American passenger, MRNA stock rose 6% in premarket trading, while NVAX and SABS climbed 2%, and INO jumped 12%, indicating strong investor interest in outbreak response stocks.
- Moderna's Research Progress: Moderna has confirmed ongoing early-stage research related to hantavirus vaccines, collaborating with the U.S. Army Medical Research Institute and Korea University’s Vaccine Innovation Center, reflecting its significant role in developing countermeasures against emerging infectious diseases.
- Investor Sentiment: Retail sentiment on Stocktwits for MRNA, SABS, INO, and NVAX is deemed 'extremely bullish', with MRNA surging 123% over the past year, SABS up 139%, and NVAX gaining 52%, highlighting strong market interest in vaccine-related stocks.
See More
Inovalis Real Estate Investment Trust Q1 Financial Results
- Decline in Rental Revenue: Inovalis Real Estate Investment Trust reported Q1 2026 rental revenue of $5.42 million, a 16.6% year-over-year decline, indicating weakened market demand and reduced leasing activity, which could negatively impact future cash flows.
- FFO Calculation Adjustment: Management excluded $17,020 of non-recurring finance income related to the Trio disposition from the Q1 2026 FFO calculation, reflecting a more conservative approach in financial reporting to ensure accurate investor understanding of financial health.
- Zero FFO and AFFO per Unit: The FFO and AFFO per unit for Q1 2026 were both nil, consistent with current occupancy levels and borrowing costs, highlighting challenges in operational efficiency and profitability that may affect investor confidence.
- Market Environment Impact: Given the significant declines in rental revenue and FFO, Inovalis may need to reassess its investment strategy and asset management to adapt to the changing market environment and maintain competitiveness.
See More
Inovio Pharmaceuticals Set to Announce Q1 Earnings on May 13
- Earnings Announcement: Inovio Pharmaceuticals is set to release its Q1 2023 earnings report on May 13 after market close, with consensus EPS estimate at -$0.33 and revenue estimate at $0.25 million, reflecting the company's commitment to financial transparency.
- Historical Performance Review: Over the past year, Inovio has exceeded EPS estimates 50% of the time and revenue estimates 25% of the time, indicating a mixed ability to meet market expectations while facing ongoing challenges.
- Estimate Changes: In the last three months, EPS estimates have seen two upward revisions and one downward revision, highlighting analysts' differing views on the company's future performance, which may impact investor confidence and stock price volatility.
- Financing Activity: Inovio recently priced a public offering of shares and warrants at $17.5 million to enhance liquidity and support its R&D projects, indicating a proactive strategy in capital raising efforts.
See More
Hantavirus Outbreak Sparks Volatility in Biotech Stocks
- Market Reaction: The hantavirus outbreak has triggered investor interest, leading biotech stocks like Moderna, Novavax, and Inovio to rise significantly over the past week, reflecting market sensitivity to vaccine development and speculative sentiment.
- CDC Risk Assessment: The Centers for Disease Control and Prevention (CDC) has stated that the risk of hantavirus transmission is extremely low, emphasizing that infection requires close contact with an infected person, which alleviates some market fears and reduces panic.
- Moderna's Development Update: Moderna announced it is working on a hantavirus treatment, currently in early stages, but its stock surged due to market confidence in its mRNA platform, demonstrating ongoing investor interest in vaccine development.
- Cautious Investor Sentiment: Despite the short-term rise in biotech stocks driven by the outbreak, analysts note that these market fluctuations are sentiment-driven and do not reflect fundamentals, urging investors to be cautious and avoid following the hype blindly.
See More
Hantavirus Outbreak Triggers Surge in Pharma Stocks
- Pharma Stock Surge: Following the WHO's May 2 warning about the hantavirus outbreak, Moderna's stock rose 7% in premarket trading, indicating market confidence in its ability to address emerging infectious diseases.
- Research Collaboration: Moderna is conducting preclinical research on hantaviruses in collaboration with the US Army Medical Research Institute, although Evercore ISI believes this will not lead to significant revenue opportunities, it highlights the agility of its mRNA platform.
- Other Companies' Performance: Inovio Pharmaceuticals jumped 11% in early trading, while Novavax rose 5%, reflecting positive market sentiment towards vaccine development firms, despite limited overall market opportunities.
- Epidemic Control Status: President Trump stated that the outbreak on the cruise ship is under control, with the WHO reporting 8 confirmed cases and 3 deaths, assessing the public health risk as low, indicating the situation is manageable.
See More
Hantavirus Outbreak Drives Pharmaceutical Stocks Up
- Pharmaceutical Stocks Surge: Following the hantavirus outbreak, pharmaceutical stocks such as Moderna, Inovio, Novavax, and Emergent Biosolutions saw significant premarket gains, with Moderna rising 7%, Inovio up 13%, and Emergent and Novavax increasing by 4% and 3% respectively, indicating heightened investor interest in outbreak-related companies.
- Market Reaction Analysis: Evercore ISI analysts noted that despite the stock increases, the revenue opportunity from hantavirus is limited, suggesting that the current price fluctuations are primarily sentiment-driven rather than based on fundamental changes, and highlighting that Moderna's mRNA platform agility is already well understood by the market.
- Epidemic Background: The World Health Organization confirmed the hantavirus outbreak on May 2, stating that the virus is transmitted by rodents; although there have been 8 reported cases and 3 deaths, the public health risk is assessed as low, indicating that the severity of the outbreak is limited.
- Government Response Measures: U.S. President Trump stated that the outbreak is under control and promised a report on the virus soon, emphasizing the government's proactive stance in managing the situation, which may further influence market sentiment and investor confidence.
See More
Rare Hantavirus Outbreak Sparks Market Response
- Outbreak Overview: The WHO reports at least six confirmed infections and three deaths linked to the hantavirus outbreak, specifically the Andes strain, which is one of the few variants associated with limited person-to-person transmission, although the public risk remains low.
- Market Response: Following the confirmation of a positive case in an evacuated American passenger, MRNA stock rose 6% in premarket trading, while NVAX and SABS climbed 2%, and INO jumped 12%, indicating strong investor interest in outbreak response stocks.
- Moderna's Research Progress: Moderna has confirmed ongoing early-stage research related to hantavirus vaccines, collaborating with the U.S. Army Medical Research Institute and Korea University’s Vaccine Innovation Center, reflecting its significant role in developing countermeasures against emerging infectious diseases.
- Investor Sentiment: Retail sentiment on Stocktwits for MRNA, SABS, INO, and NVAX is deemed 'extremely bullish', with MRNA surging 123% over the past year, SABS up 139%, and NVAX gaining 52%, highlighting strong market interest in vaccine-related stocks.
See More
